No Data
No Data
Brands that moved the day before part 2 PLANT, Sumiseki HD, Regil, etc.
<コード>Stock name closing price on the 24th ⇒ revised downward to the final major deficit due to Ahresty <5852> 647 -129 impairment recording compared to the previous day. Disgusted with potential dilution due to the issuance of Resonac <4004> 3390 -321CB. Profitable sales from fund shifts in the high price range of Hokkaido Electric Power <9509> 1155.5 -82.5. Orbic <4684> The rate of increase in sales for the fiscal year ending 20035 -16351-3 fell to the 1-digit range. Strike <6196> 4445 -365
Emerging Market Stock Digest: GENDA continues to rise drastically for 3 days, and Linkers stops high
<4586> Medlec 118 +2 repulsion. The operating profit and loss forecast for the fiscal year ending 24/12 has been revised upward from the previous deficit of 1,425 billion yen to a deficit of 1,183 billion yen (deficit of 933 million yen in the previous fiscal year results). Favorable pharmacokinetics and tolerability were shown in clinical phase 1 trials of the new drug candidate “Alto-101” in the central nervous system area, development milestones stipulated in a partnership agreement with the US drug discovery venture Alto have been achieved, and milestone revenue and paid clinical trial drug supply are expected
Makuake --- continued to decline drastically, and the scale of losses exceeded plans in the quarter even though the operating deficit for the first half of the fiscal year ended 24/9 was reduced
It continued to decline drastically. The cumulative operating profit and loss for the 2nd quarter (23/10 to 24/3) of the fiscal year ending 24/9 has been announced as a deficit of 98 million yen (deficit of 378 million yen in the same period last year). Thoroughly controlling sales and administration costs, such as advertising expenses, etc., and trying to improve cost effectiveness was a success. The full-year forecast remained unchanged with a surplus of 0.16 million yen. Although the deficit for the first half of the fiscal year shrank compared to the same period last year, according to explanatory materials, “the scale of operating losses exceeded the plan in a single quarter due to a decline in the top line”
Front market [stocks that have moved, stocks that have been created]
*Nomura Micro Science <6254> I like the upward revisions to 5460 +705 earnings and dividend forecasts. *KOA <6999> 1597 +172 look positively at the 2-digit profit increase forecast for the current fiscal year. *Nikon <7731> 1731 +167.5 Silchester became the majority shareholder of over 5%. *Komeri <8218> 3745 +335 to evaluate favorable earnings forecasts for the current fiscal year, stock buybacks, etc. *Renesas Electronics<6723> 2498.5 +217.5 US T
Strong, supported by strong US stocks [Emerging Markets Individual Stock Strategy]
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to develop steadily. On the US stock market yesterday 23rd, the Dow average rose 263.71 dollars (+ 0.69%) to 38,503.69 dollars and continued to rise for 4 days. Since the April PMI preliminary figures deteriorated unexpectedly, expectations for interest rate cuts were rekindled, and it became a stock price support factor. Also, purchases expected from the financial results of major high-tech companies also supported the market price. Buying is likely to be dominant in today's emerging markets. The fact that major indices rose in the US stock market yesterday in Tokyo
Nidec's 24/3 operating profit increased 63.1% to 163.1 billion yen, 25/3 forecast 41.0% increase to 230 billion yen
The financial results for the fiscal year ending 2024/3 announced by Nidec <6594> were sales of 2,348.202 billion yen, up 4.7% from the previous fiscal year, and operating profit of 163.106 billion yen, up 63.1% from the same period. As for the financial results for the fiscal year ending 2025/3, we plan that sales will increase 2.2% from the previous fiscal year to 2.4 trillion yen, and operating profit will increase 41.0% to 230 billion yen. No consensus was reached (around 241 billion yen). [Positive Evaluation] <6055>J Material Correction | <6467>Nichidai Correction
No Data